Azilsartan/Pioglitazone Hydrochloride

阿齐沙坦/盐酸吡格列酮

Report date: 2023/04/21 13:49:38

Base Information

Drug NameAzilsartan/Pioglitazone Hydrochloride
Drug Alias Name盐酸吡格列酮+阿齐沙坦Pioglitazone/TAK 536Actos/TAK-536阿齐沙坦盐酸吡格列酮吡格列酮+阿齐沙坦 +[11] 
ClassificationSmall molecules
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1Peroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMexicoArgentina +[5] 
CombinationsYes AzilsartanPioglitazone Hydrochloride
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A